Talecris launches IPO

Talecris Biotherapeutics has launched its ice-breaking IPO, saying it will sell 44.7 million shares at $18 to $20 per share. Analysts say the life sciences offering is solid proof that the once frozen market has begun to thaw and the Research Triangle Park-based company is leading the way. Release | Report

Suggested Articles

Bristol Myers Squibb is teaming up with Repare Therapeutics to find new synthetic lethality targets in a deal that could be worth billions.

Biotech Orpheris has been given the FDA go-ahead for a phase 2 aimed at calming the cytokine storm sometimes caused by COVID-19.

PureTech plans to start a trial in the emerging population of patients who survive COVID-19 only to suffer lasting damage in the third quarter.